Nureca
NURECA NSE
Nureca
HealthcareNSE: NURECA BSE: 543264 Medical Equipment
Key Fundamentals
MicrocapMedical EquipmentHealthcareMarket Cap
₹317 Cr
Volatility
Moderate
P/E Ratio
75.97
EBITDA
₹8.30 Cr
Return on Equity
1.15%
Debt to Equity
0.01
Book Value
₹189.44
52W High
₹358
52W Low
₹204
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has reduced debt.
- Company is almost debt free.
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -7.19% over past five years.
- Company has a low return on equity of -0.56% over last 3 years.
- Earnings include an other income of Rs.7.35 Cr.
Growth Rate
Revenue Growth
27.03% higher than
3Y
Net Income Growth
163% higher than
3Y
Cash Flow Change
117% lower than
3Y
ROE
161% higher than
3Y
ROCE
166% higher than
3Y
EBITDA Margin (Avg.)
33.17%
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.23 | 31.35 | 22.37 | 16.97 | 20.27 | 31.19 | 26.46 | 31.74 | 34.18 | 37.74 | 39.64 | 35.41 | 40.34 |
| Expenses | 24.13 | 29.97 | 26.62 | 21.4 | 22.63 | 33.54 | 30.47 | 30.54 | 34.74 | 34.47 | 36.39 | 41.19 | 36.92 |
| Operating Profit | -2.9 | 1.38 | -4.25 | -4.43 | -2.36 | -2.35 | -4.01 | 1.2 | -0.56 | 3.27 | 3.25 | -5.78 | 3.42 |
| OPM % | -13.66% | 4.4% | -19% | -26.1% | -11.64% | -7.53% | -15.15% | 3.78% | -1.64% | 8.66% | 8.2% | -16.32% | 8.48% |
| Other Income | 2.67 | 3.2 | 5.9 | -1.26 | 5.79 | 3.17 | 1.48 | 1.99 | 2.57 | 2.32 | 2.19 | 1.02 | 1.82 |
| Interest | 0.12 | 0.08 | 0.11 | 0.18 | 0.15 | 0.27 | 0.18 | 0.62 | 0.25 | 0.46 | 0.28 | 0.3 | 0.2 |
| Depreciation | 0.58 | 0.59 | 0.59 | 0.6 | 0.66 | 0.62 | 0.54 | 0.52 | 0.53 | 0.54 | 0.5 | 0.45 | 0.61 |
| PBT | -0.93 | 3.91 | 0.95 | -6.47 | 2.62 | -0.07 | -3.25 | 2.05 | 1.23 | 4.59 | 4.66 | -5.51 | 4.43 |
| Tax % | -23.66% | 25.83% | 82.11% | -35.86% | 36.64% | 585.71% | -13.85% | -20% | 34.15% | 21.13% | 19.96% | 10.71% | 30.93% |
| Net Profit | -0.71 | 2.89 | 0.17 | -4.15 | 1.66 | -0.48 | -2.8 | 2.47 | 0.81 | 3.63 | 3.73 | -6.09 | 3.07 |
| EPS in Rs | -0.71 | 2.89 | 0.17 | -4.15 | 1.66 | -0.48 | -2.8 | 2.47 | 0.81 | 3.63 | 3.91 | -6.38 | 3.22 |
Profit & Loss
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 62 | 99 | 213 | 256 | 111 | 92 | 110 | 147 | 153 |
| Expenses | 53 | 90 | 152 | 200 | 126 | 102 | 117 | 147 | 149 |
| Operating Profit | 9 | 10 | 62 | 56 | -15 | -10 | -8 | 0 | 4 |
| OPM % | 15% | 10% | 29% | 22% | -13% | -11% | -7% | 0.1% | 2.7% |
| Other Income | 0 | 0 | 3 | 8 | 7 | 11 | 12 | 8 | 7 |
| Interest | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 |
| PBT | 9 | 9 | 62 | 61 | -11 | -3 | 1 | 5 | 8 |
| Tax % | 30% | 26% | 26% | 26% | -23% | -30% | 37% | 58% | — |
| Net Profit | 6 | 6 | 46 | 45 | -8 | -2 | 1 | 2 | 4 |
| EPS in Rs | 6,230 | 6,400 | 46.37 | 44.96 | -8.25 | -1.79 | 0.85 | 2.18 | 4.38 |
| Div. Payout % | 0% | 0% | 4% | 7% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 8 | 15 | 153 | 193 | 185 | 183 | 184 | 171 |
| Borrowings | 0 | 10 | 4 | 4 | 3 | 3 | 5 | 2 |
| Other Liabilities | 15 | 9 | 19 | 12 | 8 | 10 | 11 | 13 |
| Total Liabilities | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 196 |
| Fixed Assets | 1 | 1 | 4 | 10 | 9 | 7 | 9 | 14 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 33 | 59 | 94 | 1 | 1 |
| Other Assets | 23 | 33 | 182 | 175 | 139 | 104 | 200 | 182 |
| Total Assets | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 196 |
Cash Flow
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | 0 | -8 | 35 | 1 | 10 | -3 | -19 | 3 |
| Investing | 0 | 0 | -110 | -3 | -16 | 18 | 8 | 14 |
| Financing | 0 | 8 | 92 | -7 | -2 | -1 | 0 | -20 |
| Net Cash Flow | 0 | 0 | 17 | -9 | -8 | 14 | -11 | -2 |
| Free Cash Flow | 0 | -8 | 34 | -5 | 10 | -4 | -23 | -3 |
| CFO/OP | 4 | -82 | 81 | 35 | -96 | 39 | 234 | 1,464 |
Ratios
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 47 | 6 | 4 | 14 | 6 | 11 | 19 |
| Inventory Days | 123 | 93 | 135 | 174 | 167 | 186 | 214 | 187 |
| Days Payable | 89 | 33 | 32 | 13 | 24 | 31 | 35 | 20 |
| Cash Conversion Cycle | 87 | 107 | 109 | 165 | 157 | 161 | 190 | 186 |
| Working Capital Days | 45 | 85 | 61 | 109 | 156 | 176 | 163 | 145 |
| ROCE % | — | 57% | 67% | 33% | -6% | -4% | 1% | 3% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Nureca insights
60 extracted metrics + investor summaries across FY18–FY27.
Documents
1
Disclosure Under Regulation 30 And Regulation 30A Read With Clauses 5 And5a Of Para A Of Part A Of Schedule III Of SEBI
('SEBI') (LODR) Regulations, 2015
('LODR Regulation')
20 Jun - Promoter family settlement to transfer Aryan and Payal shares to Saurabh; Aryan to resign as CEO and director. 20 Jun - Promoter family settlement to transfer Aryan and Payal shares to Saurabh; Aryan to resign as CEO and director.
2
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants ) Regulations ,2018 . 15 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants ) Regulations ,2018 .
4
Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
31 Jan - Report on buyback (Dec 18–24, 2025); promoters’ stake rose to 68.09%; 4,58,255 shares bought back. 31 Jan - Report on buyback (Dec 18–24, 2025); promoters’ stake rose to 68.09%; 4,58,255 shares bought back.
5
Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations, 2011
28 Jan - Promoters' stake increased from 64.97% to 68.09% after Dec 18–24, 2025 buyback; shares extinguished Jan 7, 2026. 28 Jan - Promoters' stake increased from 64.97% to 68.09% after Dec 18–24, 2025 buyback; shares extinguished Jan 7, 2026.
Frequently Asked Questions about Nureca
What does Nureca Ltd do?
Incorporated in 2016, Nureca Ltd is in the business of Home Healthcare and Wellness Products.[1]
Where is Nureca Ltd (NURECA) listed?
Nureca Ltd trades as NURECA on the NSE and under code 543264 on the BSE.
Which sector does Nureca Ltd belong to?
Nureca Ltd is classified under the Healthcare sector, in the Medical Equipment industry.
What is the market capitalisation of Nureca Ltd?
Nureca Ltd has a market capitalisation of ₹316.89 Cr, which places it in the Small Cap band.
What is the PE ratio of Nureca Ltd?
Nureca Ltd trades at a PE ratio of 75.97, against a book value of ₹189.44 per share.
What is the 52-week high and low of Nureca Ltd?
Over the last 52 weeks Nureca Ltd has traded between ₹204 and ₹358.
Does Nureca Ltd pay dividends?
Nureca Ltd has a dividend yield of 0.87%.
What is the Return on Equity (ROE) of Nureca Ltd?
Nureca Ltd reported a return on equity of 1.15%. Its debt-to-equity ratio is 0.01.
Company Information
Incorporated in 2016, Nureca Ltd is in the business of Home Healthcare and Wellness Products.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NURECA.md for Nureca Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.